Sayaka Fukuda

Summary

Affiliation: Mitsubishi Tanabe Pharma Corporation
Country: Japan

Publications

  1. doi request reprint A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations
    Sayaka Fukuda-Tsuru
    Department I, Pharmacology Research Laboratories II, Research Division, Mitsubishi Tanabe Pharma Corporation, 2 2 50, Kawagishi, Toda shi, Saitama 335 8505, Japan
    Eur J Pharmacol 696:194-202. 2012
  2. pmc MGAT2 deficiency ameliorates high-fat diet-induced obesity and insulin resistance by inhibiting intestinal fat absorption in mice
    Takuma Tsuchida
    Department I, Pharmacology Research Laboratories II, Research Division, Mitsubishi Tanabe Pharma Corporation, 2 2 50, Kawagishi, Toda shi, Saitama, 335 8505, Japan
    Lipids Health Dis 11:75. 2012
  3. doi request reprint Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for t
    Tomohiro Yoshida
    Research Division, Mitsubishi Tanabe Pharma Corporation, 2 2 50, Kawagishi, Toda shi, Saitama 335 8505, Japan
    Bioorg Med Chem 20:5705-19. 2012

Collaborators

  • Takuma Tsuchida
  • Kumiko Yoshida
  • Jun Anabuki
  • Tomohiro Yoshida
  • Sayaka Fukuda-Tsuru
  • Shinichi Ishii
  • Yuji Abe
  • Masahiro Takeuchi
  • Fumihiko Akahoshi
  • Shuji Sonda
  • Koji Wakimoto
  • Naoko Ueda
  • Satoko Kiuchi
  • Keigo Kosaka
  • Yoshinobu Nakamaru
  • Hiroyuki Utsumi
  • Hiroyuki Kishida
  • Nobuhiko Taniuchi
  • Yoshihito Tanaka
  • Yoko Takashina
  • Hiroshi Kitajima
  • Yoshiharu Hayashi
  • Noriko Ohashi
  • Mika Nabeno
  • Kyoko Shima
  • Naoya Masutomi
  • Sumie Sekiguchi
  • Takahiro Murozono
  • Hiroshi Sakashita
  • Reiko Tsutsumiuchi
  • Takayuki Ishige
  • Mitsuharu Nakamura
  • Hisanori Aoyama
  • Hiroko Sato
  • Akira Oku
  • Ikuko Miyaguchi
  • Tomomi Ishihara
  • Masaharu Shiotani
  • Aki Soejima

Detail Information

Publications3

  1. doi request reprint A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations
    Sayaka Fukuda-Tsuru
    Department I, Pharmacology Research Laboratories II, Research Division, Mitsubishi Tanabe Pharma Corporation, 2 2 50, Kawagishi, Toda shi, Saitama 335 8505, Japan
    Eur J Pharmacol 696:194-202. 2012
    ..The present studies indicate that teneligliptin is a potent, competitive, and long-lasting DPP-4 inhibitor that improves postprandial hyperglycemia and dyslipidemia by both single and repeated administrations...
  2. pmc MGAT2 deficiency ameliorates high-fat diet-induced obesity and insulin resistance by inhibiting intestinal fat absorption in mice
    Takuma Tsuchida
    Department I, Pharmacology Research Laboratories II, Research Division, Mitsubishi Tanabe Pharma Corporation, 2 2 50, Kawagishi, Toda shi, Saitama, 335 8505, Japan
    Lipids Health Dis 11:75. 2012
    ..To determine the physiological importance of MGAT2 in metabolic disorders and lipid metabolism in the small intestine, we constructed and analyzed Mgat2-deficient mice...
  3. doi request reprint Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for t
    Tomohiro Yoshida
    Research Division, Mitsubishi Tanabe Pharma Corporation, 2 2 50, Kawagishi, Toda shi, Saitama 335 8505, Japan
    Bioorg Med Chem 20:5705-19. 2012
    ..03 mg/kg or higher doses, significantly inhibited the increase of plasma glucose levels after an oral glucose load in Zucker fatty rats. Compound 8 g (teneligliptin) has been approved for the treatment of type 2 diabetes in Japan...